Sanofi reaches landmark Trump deal to slash US drug prices by up to 70%, cutting medication costs for millions

Sanofi has reached a landmark deal with the Trump administration to dramatically reduce prescription drug prices for millions of American patients. Under the historic agreement announced December 19, 2025, the French pharmaceutical giant will slash medicine costs by up to 70 percent through direct-to-consumer platforms. This groundbreaking partnership marks a turning point in the administration’s sweeping effort to lower medication costs nationwide.

Historic Deal Delivers 61 Percent Savings Through Medicaid Programs

The three-year voluntary agreement represents the most significant pharmaceutical pricing action to date under the Trump administration’s “Most Favored Nation” policy. Sanofi committed to aligning Medicaid prices for several wholly owned medicines with those available in other high-income countries. This means American patients on state Medicaid programs will finally pay the same prices as patients in Europe and other developed nations.

The 61 percent average price reduction applies to critical medicines treating diabetes, cardiovascular disease, neurological conditions, and certain cancers. This change alone could save state Medicaid budgets billions of dollars annually while making essential treatments more affordable for low-income Americans who depend on these programs.

Direct-to-Patient Platform Drops Drug Costs Nearly 70 Percent

Sanofi will offer consumers dramatic discounts through the new TrumpRx direct-to-patient platform launching in early 2026. Patients purchasing medications directly bypass traditional middlemen and pharmacy markups, translating to average savings of nearly 70 percent on qualifying medicines. This innovative approach gives American patients access to affordable medications without insurance complications.

CEO Paul Hudson stated the company is “moving forward with a plan that lowers medicine prices for Americans now and strengthens the vital role of the US in delivering breakthroughs into the future.” Specific examples include insulins at $35 per month—a dramatic reduction from standard pricing—and the blood thinner Plavix dropping from list prices exceeding $750 to just $16 per dose.

Nine Pharmaceutical Companies Embrace Trump Administration Framework

Company	Key Drug Price Reduction	Savings %
Sanofi	Plavix: $756 → $16	Nearly 70%
Merck	Januvia: $330 → $100	~70%
Novartis	Mayzent: $9,987 → $1,137	~88.6%
Gilead Sciences	Epclusa: $24,920 → $2,425	~90.3%
Bristol Myers Squibb	Reyataz: $1,449 → $217	~85%

Sanofi joins eight other major pharmaceutical manufacturers—Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, and Novartis—in embracing the Trump administration’s pricing framework. Together, these nine companies represent 14 of 17 major drugmakers that have now signed deals. The collective $150 billion investment commitment in U.S. manufacturing demonstrates the industry’s confidence in the policy while delivering tangible benefits to American patients.

“By working constructively with the Administration, we are moving forward with a plan that lowers medicine prices for Americans now and strengthens the vital role of the US in delivering breakthroughs into the future. These sweeping changes to the US pharmaceutical landscape amplify the critical and urgent need for advanced economies to recognize the value of innovation.”

— Paul Hudson, Chief Executive Officer of Sanofi

Sanofi Manufacturing Expansion and Tariff Relief Support U.S. Investment

The agreement provides Sanofi with a three-year exemption from Section 232 tariffs on imported products—a significant economic incentive. The company employs more than 13,000 people across 15 U.S. sites, including operations in Massachusetts and New Jersey. This includes over 2,200 research scientists and staff at six R&D campuses and approximately 4,000 workers in manufacturing facilities.

Sanofi is building on an already-announced $20 billion investment plan through 2030. The agreement commits the company to upgrading existing manufacturing facilities, building new supply capacity, and expanding manufacturing partnerships. This manufacturing expansion strengthens America’s domestic pharmaceutical production and reduces reliance on international supply chains during health emergencies.

What Does This Deal Mean for Millions of American Patients?

For American families struggling with prescription drug costs, this agreement delivers immediate relief. The Medicaid price reductions influence state government healthcare budgets, potentially freeing resources for additional patient care programs. More critically, the TrumpRx platform launch will enable uninsured and underinsured patients to access medicines at unprecedented discounts.

The December 19, 2025 announcement represents the culmination of months of negotiations following President Trump’s July 31 letter to pharmaceutical executives outlining four specific requests. Sanofi confirmed this voluntary agreement meets all four requirements while establishing a sustainable framework for continued U.S. pharmaceutical innovation. The company stated the agreement does not impact its growth strategy or financial outlook during the three-year period, indicating the pricing model remains profitable despite dramatic cost reductions.

Sources

• Sanofi Official Press Release – December 19, 2025 announcement and agreement details
• White House Fact Sheet – Official Trump administration pharmacy pricing policy framework and price examples
• Investing.com – Financial analysis and market response to pharmaceutical pricing deals